VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE PHASE I CLINICAL TRIAL OF LM-350 "CDH17 ADC" IN AUSTRALIA

VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE PHASE I CLINICAL TRIAL OF LM-2417 "NaPi2b/4-1BB BISPECIFIC ANTIBODY" IN CHINA

VOLUNTARY ANNOUNCEMENT - IND APPLICATION OF TQF3250 CAPSULES "GLP-1 RECEPTOR AGONIST" ACCEPTED BY NMPA

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 AUGUST 2025

VOLUNTARY ANNOUNCEMENT - ZONGERTINIB TABLETS APPROVED FOR MARKETING

VOLUNTARY ANNOUNCEMENT - DATA FROM FOUR STUDIES OF "TQC3721 (PDE3/4 INHIBITOR)", "TQC2731 (TSLP MONOCLONAL ANTIBODY)" AND "TQC3403 (UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE POWDER FOR INHALATION)" PRESENTED AT ERS 2025

VOLUNTARY ANNOUNCEMENT - HER2-SELECTIVE TKI "ZONGERTINIB" ONCE AGAIN GRANTED BREAKTHROUGH THERAPEUTIC DESIGNATION BY CDE

VOLUNTARY ANNOUNCEMENT - LM-302 "CLDN18.2 ADC" INCLUDED IN THE BREAKTHROUGH THERAPEUTIC DESIGNATION PROCESS